Open study evaluating the onset of antipsychotic action of olanzapine in the treatment of patients with schizophrenia, schizophreniform or schizo-affective disorder

International Journal of Psychiatry in Clinical Practice

Volumn 8, Issue 4, 2004, Pages 199-204

  Peuskens, Joseph ^a   Mertens, Claudine ^b   Geerts, Stefan ^b   Gillain, Benoit ^c   Van Vleymen, Betty ^d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b St Camillas Hospitaal ^*  (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d Medical Department   (Belgium)

Author keywords

Atypical antipsychotic; Olanzapine; Onset of antipsychotic action; Open label; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE;

ADULT; AGITATION; ANXIETY; ARTICLE; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIGESTIVE SYSTEM DISEASE; DISEASE EXACERBATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEGATIVE SYNDROME; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; POSITIVE SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCORING SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE;

EID: 10044244864     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500410005667     Document Type: Article

References (20)

1. Zyprexa SPC, EMEA (2004) Available at www.emc.vhn.net/public
2. Beasley CM Jr, Tollefson G, Tran P, et al. The Olanzapine HGAD Study Group (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14: 111-3.
3. Beasley CM Jr, Sanger T, Satterlee W et al. Olanzapine HGAP Study Group (1996) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124: 159-67.
4. Tollefson GD, Beasley CM Jr, Tran PV et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154: 457-65.
5. Beasley CM Jr, Hamilton S, Crawford AM et al (1997) The Olanzapine E003 Study Group. Olanzapine versus haloperidol: acute phase results of the International double-blind olanzapine trial. Eur Neuropsychopharmacol 7: 125-37.
6. Tollefson GD, Sanger TM, Lu MK et al (1998) Depressive signs and symptoms in schizophrenia - a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55: 250-8.
7. Gomez J-C, Crawford AMK (2001) Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter trial. J Clin Psychiatry 62 (2): 6-11.
8. Bilder R, Goldman R, Volavka J et al (2002) Neurocognitive effects of clozapine, olanzapine, risperidone and haloperidol in patient with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018-28.
9. Tran P, Dellva M, Tollefson G (1998) Oral olanzapine vs oral haloperidol in the maintenance treatment of schizophrenia and related psychosis. Br J Psychiatry 172: 499-505.
10. Hamilton SH, Revicki DA, Genduso LA et al (1997) Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double blind trial. Neuropsychoapharmacology 18: 41-9.
11. Kay S, Ople L, Fiszbein A (1986) Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawada, NY: Multi-Health Systems.
12. Lingjaerde O, Ahlfors UG, Bech P et al (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 76 (suppl 334): 1-100.
13. American Psychiatric Association (1997) Practice Guideline for the Treatment of Patients with Schizophrenia. Washington, DC: American Psychiatric Association.
14. The Expert Consensus Guideline Series (2003) Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 64 (suppl. 12): 24
15. Agid O, Kapur S, Arenovich T, Zipursky R (2003) Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60: 1228-35.
16. Leucht S (2004) Amisulpride, a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomised controlled trials. Int J Neuropsychopharmacol 7 (suppl 1): S15-20.
17. Beasley CM, Tollefson GD, Tran PV (1997) Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 58 (suppl 10): 7-12.
18. Dursun SM, Gardner DM, Bird DC et al (1999) Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Can J Psychiatry 44: 701-4.
19. Baker R, Kinon W, Maguire G et al (2003) Effectiveness of rapid initial dose escalation of up to 40 mg per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 23: 342-8.
20. Kinon B, Basson B, Gilmore J et al (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62: 92-100.